Guselkumab治疗生物制剂初治银屑病关节炎一年疗效与安全性
DISCOVER-2 III期试验在739例生物制剂初治的活动性银屑病关节炎患者中评估Guselkumab(IL-23p19抑制剂)治疗52周的疗效与安全性。第52周时,每4周和每8周给药组的ACR20应答率分别维持在71%和75%,多样临床表现持续改善,影像学进展低,安全性良好。
要点
- Guselkumab每4周或每8周给药至52周,ACR20应答率分别达71%和75%。
- 第24周达到的ACR50/ACR70、皮肤应答及附着点炎/指炎缓解在52周维持。
- 52周内严重感染少见,未出现机会性感染或死亡,风险获益良好。
核心结论
- 在生物制剂初治的银屑病关节炎患者中,Guselkumab至第52周持续改善多领域表现并维持良好风险获益。
研究设计与样本
- III期DISCOVER-2随机对照试验纳入739例活动性PsA成人患者(≥5个肿胀和≥5个压痛关节,CRP≥0.6 mg/dl),随机接受Guselkumab 100 mg每4周、每8周或安慰剂(第24周交叉至每4周)。
主要发现
- 第52周时,每4周组ACR20应答率为71%(173/245),每8周组为75%(185/248),第24周后的应答得以维持。
- 第24周达到的ACR50/ACR70、皮肤应答、最小或极低疾病活动度、指炎或附着点炎缓解在第52周维持。
- 持续Guselkumab治疗至第52周维持低水平影像学进展及身体功能和生活质量改善。
- Guselkumab随机组严重感染少见,0-24周为4/493(0.8%),24-52周为3/493(0.6%),无剂量方案反应证据或增加。
- 未发生机会性感染或死亡。
临床怎么用
- 对于生物制剂初治的活动性银屑病关节炎患者,Guselkumab每4周或每8周方案至52周可维持多领域疗效且安全性良好。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Guselkumab, a human monoclonal antibody specific to interleukin-23p19, demonstrated efficacy and safety versus placebo through week 24 of the phase III DISCOVER-2 trial in biologic-naive patients with psoriatic arthritis (PsA). Here we report 1-year DISCOVER-2 findings. METHODS: Adults with active PsA (≥5 swollen and ≥5 tender joints; C-reactive protein level ≥0.6 mg/dl) despite standard nonbiologic treatment were randomized to receive subcutaneous injections of guselkumab 100 mg every 4 weeks, guselkumab 100 mg at week 0, week 4 and every 8 weeks thereafter, or placebo with crossover to guselkumab 100 mg every 4 weeks at week 24. We primarily evaluated clinical efficacy through week 52 by imputing missing data (nonresponse for categorical end points; no change/using multiple imputation for continuous end points). Observed radiographic scores and adverse events (AEs) were summarized. RESULTS: Of 739 randomized, treated patients, 93% completed week 52. The proportions of patients in whom a ≥20% improvement from baseline in American College of Rheumatology criteria (ACR20) was achieved were maintained after week 24, reaching 71% (173 of 245) and 75% (185 of 248) for patients randomized to receive treatment every 4 weeks or every 8 weeks, respectively, by week 52. The proportions of patients in whom ACR50/ACR70 and skin responses, minimal or very low disease activity, and dactylitis or enthesitis resolution were achieved at week 24 were also maintained through week 52. Further, low levels of radiographic progression, along with improvements in physical function and health-related quality of life, were sustained through week 52 with continued guselkumab treatment. Few patients experienced serious infections through week 52, with no evidence of a dosing regimen response or increase from weeks 0-24 (4 of 493 [0.8%]) to weeks 24-52 (3 of 493 [0.6%]) among guselkumab-randomized patients. No patient developed an opportunistic infection or died. CONCLUSION: In biologic-naive PsA patients, guselkumab provided sustained improvements across diverse manifestations and maintained a favorable risk-benefit profile through week 52.
引用
- McInnes IB, Rahman P, Gottlieb AB, et al. Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis. Arthritis Rheumatol. 2021. PMID: 33043600. doi:10.1002/art.41553
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。